Personalized treatment of glioblastoma – pro
Abemaciclib is in an active clincalt trial, NCT02981940. This research study is studying a targeted therapy as a possible treatment for recurrent glioblastoma (GBM). This research study is a Phase 0/II clinical trial. In laboratory studies, Abemaciclib was able to enter the brain, stop CDK 4 and CDK 6 from making cells, and slow the growth of mice Glioblastoma. In this research study, the investigators are looking to see how safe and effect Abemaciclib is with the participant type of cancer. It is currently an E/I therapy.
Pilot data fomr Lazaridis et al, indicate that molecularly matched targeted brain tumor treatment is well tolerated and associated with prolonged disease control and longer survival compared to patients who received molecularly unmatched empiric therapy or patients with tumors lacking those molecular markers and genomic alterations that were selected for this study. However, this is a very early study and only a retrospective study.
Cao Y, Li X, Kong S, Shang S, Qi Y. CDK4/6 inhibition suppresses tumour growth and enhances the effect of temozolomide in glioma cells. J Cell Mol Med. 2020 May;24(9):5135-5145
Lazaridis, L., Schmidt, T., Oster, C. et al. Precision neuro-oncology: a pilot analysis of personalized treatment in recurrent glioma. J Cancer Res Clin Oncol (2022).